Fig. 7: Sustained Akt activation is required for in PDGF-BB induced myofibroblast transition of Smpd1−/− SMCs. | Cell Death & Disease

Fig. 7: Sustained Akt activation is required for in PDGF-BB induced myofibroblast transition of Smpd1−/− SMCs.

From: Contribution of p62/SQSTM1 to PDGF-BB-induced myofibroblast-like phenotypic transition in vascular smooth muscle cells lacking Smpd1 gene

Fig. 7

a Representative images and quantitative data show the effects of PDGF-BB (30 ng/ml) on the phosphorylation of Akt and Erk-1/2 in in Smpd1+/+ or Smpd1−/− SMCs. *P < 0.05, **P < 0.01 (n = 4). b, c Representative images and quantitative data show the effect of Akt inhibitor LY294002 (50μmol/l) on PDGF-BB-induced changes in Akt phosphorylation, p62/SQSTM1, and FSP-1 in Smpd1+/+ or Smpd1−/− SMCs. SMCs were treated with or without PDGF-BB (30 ng/ml) for 2 h for Akt phosphorylation or for 24 h for analysis of p62/SQSTM1 and FSP-1. *P < 0.05, **P < 0.01 (n = 4). d Real-time RT-PCR analyses of IL-6 and IL-18 mRNA expression in Smpd1−/− SMCs treated with or without PDGF-BB (30 ng/ml) for 24 h in the presence or absence of LY294002 (50μmol/l). *P < 0.05, **P < 0.01 (n = 6). e Representative immunofluorescence images of Smpd1+/+ or Smpd1−/− SMCs treated with or without PDGF-BB (30 ng/ml) in the presence or absence of LY294002 (50μmol/l) for 24 h. The experiment was repeated at least three times

Back to article page